PUT - SPRINTER OPEN END - BIOGEN IDEC | Delayed Deutsche Boerse AG 01:43:11 03/06/2024 pm IST | ||
| 8.84 EUR | -0.90% |
|
| 1 month | -9.07% | ||
| 3 months | -3.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 8.84 | -0.90% |
| 31/24/31 | 8.92 | -6.50% |
| 30/24/30 | 9.54 | -3.05% |
| 29/24/29 | 9.84 | +2.39% |
| 28/24/28 | 9.61 | +1.16% |
Delayed Quote Deutsche Boerse AG
Last update June 03, 2024 at 01:43 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VU8LNL |
| ISIN | DE000VU8LNL8 |
| Date issued | 14/06/2023 |
| Strike | 319.1 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.84 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.22 € |
|---|---|
| Lowest since issue | 1.45 € |
| Spread | 0.16 € |
| Spread % | 1.78% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
224.9
USD
Average target price
284.8
USD
Spread / Average Target
+26.60%
- Stock Market
- Certificates
- Certificat
